Alectinib as a treatment option following recovery from crizotinib‑induced interstitial lung disease in patients with 
anaplastic lymphoma kinase‑positive advanced non‑small‑cell lung cancer

Nukaga,Shigenari; Naoki,Katsuhiko; Kamo,Tetsuro; Masuzawa,Keita; Yasuda,Hiroyuki; Soejima,Kenzo; Betsuyaku,Tomoko

doi:10.3892/mco.2016.838

June-2016 Volume 4 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2016 Volume 4 Issue 6

Full Size Image

Article

Alectinib as a treatment option following recovery from crizotinib‑induced interstitial lung disease in patients with anaplastic lymphoma kinase‑positive advanced non‑small‑cell lung cancer

Authors:
- Shigenari Nukaga
- Katsuhiko Naoki
- Tetsuro Kamo
- Keita Masuzawa
- Hiroyuki Yasuda
- Kenzo Soejima
- Tomoko Betsuyaku
View Affiliations / Copyright

Affiliations: Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo 160‑8582, Japan
Pages: 1085-1087
|
Published online on: March 30, 2016

https://doi.org/10.3892/mco.2016.838
Expand metrics +

Abstract

Crizotinib is a tyrosine kinase inhibitor that displays antitumor activity against anaplastic lymphoma kinase (ALK)‑positive advanced non‑small‑cell lung cancer. However, crizotinib‑associated interstitial lung disease (ILD) has been reported as an infrequent, but potentially fatal complication. We herein describe the case of a 63‑year‑old male patient with ALK‑rearranged advanced lung adenocarcinoma. Chest computed tomography (CT) revealed extensive bilateral ground‑glass opacity and airspace consolidation with traction bronchiectasis on day 27 of crizotinib therapy. No signs of infection or left heart failure were identified and we considered the lesions to be consistent with crizotinib‑induced ILD. Following corticosteroid treatment and discontinuation of crizotinib, CT revealed improvement of ILD, but also showed regrowth of the tumor. Alectinib, a novel alternative ALK inhibitor, was initiated, and has been successfully continued, with neither disease progression nor recurrence of ILD. The present case indicates that alectinib may be considered as an alternative agent in cases of crizotinib‑induced ILD, irrespective of the pattern of ILD, i.e., a diffuse alveolar damage (DAD) or non‑DAD pattern, with careful observation.

View Figures

View References

1	Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
2	Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
3	Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M and Nakagawa K: Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol. 31:e15–e17. 2013. View Article : Google Scholar : PubMed/NCBI
4	Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, et al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1–2 study. Lancet Oncol. 14:590–598. 2013. View Article : Google Scholar : PubMed/NCBI
5	Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, et al: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 15:1119–1128. 2014. View Article : Google Scholar : PubMed/NCBI
6	Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M and Cadranel J: Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: A retrospective observational cohort study with a systematic literature review. J Thorac Oncol. 10:1148–1155. 2015. View Article : Google Scholar : PubMed/NCBI
7	Yanagisawa S, Inoue A, Koarai A, Ono M, Tamai T and Ichinose M: Successful crizotinib retreatment after crizotinib-induced interstitial lung disease. J Thorac Oncol. 8:e73–e74. 2013. View Article : Google Scholar : PubMed/NCBI
8	Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B and Los G: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6:3314–3322. 2007. View Article : Google Scholar : PubMed/NCBI
9	Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI